Patients current disease state must be one for which there is no known curative therapy
Current disease state must be one for which there is currently no known effective therapy
Subjects current disease state must be one for which there is no known curative therapy
Patients who have an option for any treatment with proven clinical benefit for their lymphoid malignancy at current state of disease.
Current disease state must be one for which there is currently no known curative therapy
Patients who have a standard curative option for their lymphoid malignancy at current state of disease are excluded; for eligibility on this trial, allogeneic stem cell transplantation is not considered a standard curative option
Participant's current disease state must be one for which there is no known curative therapy.
Patient with a history of genetic prothrombotic state
Prior diagnosis of thrombosis or known hypercoagulable state
Subjects current disease state must be one for which there is no known curative therapy
Subjects current disease state must be one for which there is no known curative therapy
Subjects current disease state must be one for which there is no known curative therapy, or in the case of a new diagnosis there must be ? % chance of cure if given standard-of-care chemotherapy (prognosis to be determined at the discretion of the treating physician)
Any immunodeficiency disease or immune-compromised state
Patients who have any option for other treatment for B-cell NHL at the current state of disease.
Patients who have a standard curative option for their lymphoid malignancy at current state of disease are excluded; for eligibility on this trial, allogeneic stem cell transplantation is not to be considered a standard curative option
Patients current disease state must be one for which there is no known curative therapy
Patients who have a standard curative option for their lymphoid malignancy at current state of disease are excluded; for eligibility on this trial, allogeneic stem cell transplantation is not to be considered a standard curative option
Patient's current disease state must be one for which there is no known curative therapy
History of thrombosis due to a known inherited hypercoagulable state
Incarceration/ward of the state status
Eligible for state quitline services
Current disease state must be one for which there is currently no known curative therapy.
Patients who have an option for other treatment for B-ALL at the current state of disease.
